ArticleFrontiers in pharmacology2026
DZ-1-artesunate conjugate induces mitochondria-mediated, reactive oxygen species-dependent apoptosis in colorectal cancer tumoroids.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We previously reported that the heptamethine cyanine dye-conjugated artesunate (DZ-1-ART) induces apoptosis in monolayer (2D) cell culture models. However, in 2D cultures, cells grow on flat, rigid plastic surfaces that fail to recapitulate the three-dimensional architecture of tumor tissues. This artificial environment alters cell polarity, morphology, and mechanical signaling, leading to non-physiological behavior. To overcome these limitations, we developed patient-derived tumoroids to assess the tumoricidal efficacy of the DZ-1-ART conjugate. In this study, tumoroids were established from fresh tissue samples of a malignant neoplasm of the sigmoid colon. The anticancer activity of DZ-1-ART was evaluated in these tumoroids. Propidium iodide staining confirmed DZ-1-ART-induced cytotoxicity, while TUNEL and immunoblotting assays demonstrated that this cytotoxicity was mediated by apoptosis. Furthermore, MitoTracker staining and near-infrared fluorescence indicated mitochondrial localization of DZ-1-ART. The JC-1 assay showed disruption of mitochondrial membrane potential following DZ-1-ART treatment. Additionally, deferoxamine and MitoTEMPO pretreatment revealed that DZ-1-ART induced mitochondria-mediated reactive oxygen species (ROS) generation in tumoroids. Collectively, these findings suggest that DZ-1-ART acts as a potent mitochondria-targeting anticancer agent with potential for precision therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.